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Abstract
Bone marrow-derived cells were demonstrated to improve organ function, but the lack of
cell retention within injured organs suggests that the protective effects are due to factors
released by the cells. Herein, we tested cell therapy using early outgrowth cells (EOCs) or
their conditioned media (CM) to protect the retina of diabetic animal models (type 1 and type
2) and assessed the mechanisms by in vitro study. Control and diabetic (db/db) mice (8
weeks of age) were randomized to receive a unique intravenous injection of 5×105EOCs or
0.25 ml thrice weekly tail-vein injections of 10x concentrated CM andWystar Kyoto rats ren-
dered diabetic were randomized to receive 0.50 ml thrice weekly tail-vein injections of 10x
concentrated CM. Four weeks later, the animals were euthanized and the eyes were enu-
cleated. Rat retinal Müller cells (rMCs) were exposed for 24 h to high glucose (HG), com-
bined or not with EOC-conditioned medium (EOC-CM) from db/m EOC cultures. Diabetic
animals showed increase in diabetic retinopathy (DR) and oxidative damage markers; the
treatment with EOCs or CM infusions significantly reduced this damage and re-established
the retinal function. In rMCs exposed to diabetic milieu conditions (HG), the presence of
EOC-CM reduced reactive oxygen species production by modulating the NADPH-oxidase
4 system, thus upregulating SIRT1 activity and deacetylating Lys-310-p65-NFκB, decreas-
ing GFAP and VEGF expressions. The antioxidant capacity of EOC-CM led to the preven-
tion of carbonylation and nitrosylation posttranslational modifications on the SIRT1
molecule, preserving its activity. The pivotal role of SIRT1 on the mode of action of EOCs or
their CM was also demonstrated on diabetic retina. These findings suggest that EOCs are
effective as a form of systemic delivery for preventing the early molecular markers of DR
and its conditioned medium is equally protective revealing a novel possibility for cell-free
therapy for the treatment of DR.
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Introduction
With the incidence of diabetes increasing at an alarming rate, the number of people with dia-
betic retinopathy (DR) is expected to grow from 126.6 million to 191 million by 2030 [1]. The
known pathways, including oxidative stress, increased formation of AGEs, and activation of
protein kinase-C and hexosamine pathways [2,3], appear to cross-talk. For this reason, new
strategies to prevent these devastating complications are needed.
Cellular therapies for the treatment of degenerative retinal diseases such as DR and age-rela-
tedmacular degeneration have been developed recently using a variety of cell types, including
pluripotent stem cell- retinal pigment epithelium (RPE), bone marrow- or umbilical cord-
derived mesenchymal stem cells, foetal neural or retinal progenitor cells, and stem cell-derived
adult RPE [4–6]. Among many proposed cell types, circulating or bone marrow-derived endo-
thelial progenitor cells (EPCs) have been the main cells used in clinical trials [7,8]. The mecha-
nisms by which these cells exert their beneficial effects remain unclear, and studies have
documented only minimal retention of administered cells within organs that have nevertheless
sustained functional and structural improvements [9,10]. So-called early out growth cells
(EOCs), defined by theidentification of their cell surface markers, have gained attention for
their secretory feature of releasing antifibrotic and anti-oxidative stress factors [11–15]. Gilbert
and colleagues described a successful treatment for diabetic nephropathy using a single infu-
sion of EOCs in an experimental model of type 2 diabetes mellitusmice [14]. Similar findings
were demonstrated in db/db mice treated with conditioned medium from EOCs, suggesting
that the effects were mediated through released factors [15]. Mass spectrometric analysis of the
EOC-conditioned medium (EOC-CM) identified proteins that regulate cellular functions
implicated in fibrosis and proteins involved in stress responses, such as HSP-19, glutathione S
transferase (GST1), peroxiredoxin, superoxide dismutase (SOD), thioredoxin, and heme oxy-
genase-1 [15]. These results indicate that EOCs display a great capacity for secreting soluble
factor(s) with potent antioxidant activity that, when injected intravenously, replicate the salu-
tary effects of the cells themselves.
Muller cell, the predominant glial cell in the retina, has its cell body residing in the inner
nuclear layer and span all retinal layers, interacts with neighbouring neurons, being part of the
outer and inner limiting membranes [16]. Due to this, Muller cells monitor the retinal structure
and function. Muller cell processes wrap around retinal blood vessels thus controlling retinal
barrier [17] but also mantain neurons by releasing trophic factors and recycling neurotransmit-
ters and controlling ionic balance in the extracellular space [18]. These two both features are
present in the pathogenesis of DR. Under sustained stress, as observed in diabetes, the Muller
cells produce pro-inflamatory cytokines to restore the retinal homeostasis [19] upregulating
glial fibrillary acidic protein (GFAP) [18] and VEGF [20] leading to a glial reaction and blood
barrier hyper-permeability [21].
Sirtuins (SIRTs) are a family of deacetylases that require NAD+ as a cofactor for the deace-
tylation reaction. SIRT1 has been shown to play a role in gene silencing, apoptosis, senescence,
and aging [22,23]. As it is NAD+ dependent, SIRT1 acts in some loci by removing the acetyl
group from the histonechromatin [23], but it can also suppress other proteins by deacetylation,
including the nuclear factor (NF)κB-p65subunit protein [24]. Under certain stimuli, such as
reactive oxygen species (ROS), SIRT1 is inactivated, thus suppressing its deacetylase activity
[25]. This redox-sensitive particularity of SIRT1 is explained by a reduction in substrate NAD+
[26] or by the post-translational modification of the SIRT1 protein [27]. Our group recently
described the mechanism of glial reaction in Müller cells under diabetic conditions through
acetylation of the NFκB-p65subunit due to impairment of SIRT1 activity [28].
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In light of this evidence, the aim of this study was to investigate whether cellular therapy
using intravenously injected cultured EOCs or their conditioned medium (CM) protect the ret-
ina of db/db mice and of experimentally diabetic WKY rats from the effects of the diabetic
environment. To address the possible mechanism involved in the observed in vivo findings, ret-
inal Müller cells (rMC) were exposed to high glucose (HG) and treated with CM from db/m
EOCs (EOC-CM). Our results indicate that the intravenous infusion of EOCs or their CMmit-
igates the early DR markers, namely GFAP and VEGF, and oxidative markers in diabetic reti-
nas of db/db mice and fully restored retinal function (evaluated through eletrophysiological
means) in diabetic WKY rats. In rMCs exposed to HG, EOC-CM led to a decrease in ROS pro-
duction via NOX4 system. The equitable redox status re-establishes SIRT1 activity through
prevention of the posttranslational modification of the SIRT1 molecule, which in turn deacety-
lates Lys-310-p65-NFκB and decreases glial reaction, preventing the early DR markers.
Methods
Animal model and experimental design
Protocol 1. The animal study complied with the ARVO Statement for the Use of Animals
in Ophthalmic and Vision Research. The Jackson Laboratory (Bar Harbor, ME) provided 36
male, diabetic db/db (BKS.Cg-Dock7 m +/+ Leprdb/J) 6-week-old and 12 age-matched db/m
(Dock7 m+/+ Leprdb; heterozygote from the same colony) mice. At 8 weeks of age, the db/db
mice were randomized to receive a tail-vein injection of medium only (DPBS saline; n = 4) or
5x105 EOCs derived from db/m mice (n = 5) (study design A) or to receive 0.25 ml thrice
weekly tail-vein injections of either: (1) EBM-2 medium (EBM-2, n = 8), or (2) 10X concen-
trated CM generated from EOCs derived from db/m mice (db/m CM, n = 10) (study design B).
The db/m mice served as non-diabetic controls (n = 5). The mice were housed in a tempera-
ture-controlled room (22°C) with a 12h:12h light:dark cycle with free access to food and water.
All animal studies were approved by the St. Michael’s Hospital Animal Ethics Committee in
accordance with the Guide for the Care and Use of Laboratory Animals (NIH publ. no. 85–23,
revised 1996). Four weeks after both treatments, the animals were euthanized, samples were
collected, and retinal tissues were harvested.
Protocol 2. This study protocol was approved by the local committee for ethics in animal
research (CEEA/IB/UNICAMP, protocol number 3551–1). Experimental diabetes was induced
in 6-week-old maleWKY by intravenous injection of streptozotocin (60 mg/kg in 0.5-M sodium
citrate buffer, pH4.5; Sigma, St. Louis, MO, USA); the control animals received vehicle alone.
Blood glucose levels were measured 72 h after the injection and values15 mmol/L were consid-
ered diabetic. The animals were randomized to receive a tail-vein injection of 0.5 ml thrice weekly
tail-vein injections for 2 weeks of either: (1) EBM-2 (WKY-DM+EBM-2, n = 4), or (2) 10X con-
centrated CM generated from EOCs derived fromWKY (WKY-DM+CM, n = 4). TheWKY rats
diabetic untreated (WKY-DM, n = 4) and non-diabetic (WKY-CT, n = 5) served as experimental
controls. The rats were housed in a temperature-controlled room (22°C) with a 12h:12h light:
dark cycle with free access to food and water. Two weeks of the treatment, the animals were sub-
mitted to full flash electroretinography test (ERG).
Metabolic functional parameters. Body weight and blood glucose (Accu-check Advan-
tage, Roche, Mississauga, ON) were determined bi-weekly.
Full-flash ERG recording. Retinal function was measured at the end of the study using
the UTAS-E3000 system (LKC Technologies Inc., Gaithersburg, MD, USA) as previously
described [28]. The pupils were dilated with tropicamide (Mydriacyl 0.5%; Allergan, Irvine,
CA, USA). General anesthesia was induced with ketamine and xylazine (75 and 7.5 mg/kg,
respectively) under dim red illumination (λmax = 650 nm). The measurements were taken
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after overnight dark adaptation. An intensity-response series was recorded using a series of
ganzfeld flashes with 0.25 cd.s/m2 intensity. Recordings were amplified and digitized using a
24-bit A/D converter band passed from 0.3 to 300 Hz with a 50-Hz notch filter.
Tissue preparation and histology. Mice were euthanized 4 weeks after the initiation of
the treatments. Eyes were collected and fixed in 10% neutral buffered formalin, followed by
embedding in cryostat matrix (Tissue-Tek, Sakura, Kobe, Japan) or snap freezing in liquid
nitrogen. Formalin-fixed eyes were routinely processed, embedded in paraffin, and sectioned.
Bone marrow harvesting and cell culture. The EOCs were cultured as described [12,29].
To produce the EOCs, bone marrow cells were collected from the femora and tibiae of 3- to
4-week-old male db/m mice or WKY rats and cultured in EGM-2 (Lonza, Walkersville, MD) at
37°C with 5% CO2 for 7–10 days when the total cell number reached ~2 x 106 per culture dish.
An EOC-conditioned medium was then generated by incubating the EOCs with serum-free
endothelial basal medium-2 (EBM-2) (Lonza, Walkersville, MD) for 24 hours. The medium
was collected, centrifuged, and concentrated 10-fold using a centrifuge filtration column (Milli-
pore, Billerica, MA). EOC CM was then filtered using a 0.45 μm filter (Millipore, Billerica,
MA). EBM-2 medium (Lonza, Walkersville, MD) was concentrated and filtered as a control.
Aliquots of the concentrated CM and EBM-2 were stored at -80°C.
EOC-CM generation. EOC-CM was generated as previously described [12,14]. The
medium from subconfluent EOCs cultivated in a serum-free EBM-2 (Lonza) for 24 h was col-
lected and used for in vitro experiments. Serum-free EBM-2 medium served as a control.
Immunohistochemistry in retinal tissues. Retinal sections (4 μm) were incubated with
antibody against GFAP (DakoCytomation, Carpinteria, CA), VEGF (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), nitrotyrosine (NT) (Upstate Biotechnology, Lake Placid, NY),
8-hydroxy-deoxiguanosine (8-OHdG) (JaICA;NikkenSEIL Co. Ltd, Shizuoka, Japan), and
SIRT1 (Cell Signaling Technology, Danvers, MA) overnight at 4°C. The slides were then incu-
bated with the appropriate secondary antibodies. The semi quantitative analyses were per-
formed using the Leica Application Suite (Leica Microsystems, Wetzlar, Germany) in nine
non-consecutive retinal sections divided among three slides per animal, per group, under high-
powered microscopic viewing (×400) (Zeiss, Jena, Germany).
In vitro studies
Transformed rat retinal Müller cell line (rMC-1). Vijay J. Sarthy, PhD (Northwestern
University, Evanston, IL) kindly provided the rMC-1, which was grown in DMEM-containing
5 mM of glucose, 10% foetal bovine serum (FBS), 24 mmol/L of NaHCO3, 10 mmol/L of
HEPES, and 10.000 U/L of penicillin/streptomycin. The cells were maintained in a humidified
incubator at 37°C and 5% CO2. At 70% of confluence, rMC-1 cell cultures were serum-starved
to 1% FBS, then exposed for 24h with DMEM with 5.5 mmol/L glucose (NG), DMEM with 25
mmol/L glucose (HG), DMEM with 25 mmol/L glucose plus 10% of 10X concentrated db/m
EOC-CM (HG+CM), or with other treatments as specified; DMEM with 5.5 mmol/L glucose
plus 19.5 mmol/L of mannitol (MAN) was used as an osmotic control. The cytotoxicity of the
treatments on rMCs was determined by thiazolyl blue tetrazolium bromide (MTT) colorimet-
ric assay [30].
Transient transfection with siRNAs. The small interfering RNA (siRNA) duplexes and
scrambled siRNA corresponded to rat SIRT1 (Santa Cruz Biotech) and rat NOX4 (Dharmacon,
Lafayette, CO). The transient transfection of siRNAs was carried out using Lipofectamine1
transfection reagent (Life technologies Carlsbad, CA [31].
Immunofluorescence in Müller cells. The immunofluorescence was performed as
described [28]. The cells were incubated with anti-GFAP, anti-VEGF, or anti-SIRT1 antibodies
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(Santa Cruz) followed by the appropriate secondary antibody (Santa Cruz). Afterward, the sec-
tions were rinsed and cover-slipped with VECTASHIELD1, which is used for nuclei staining
(Vector Laboratories, Burlingame, CA). The slides were examined under a scanning micro-
scope (CLSM; Zeiss) with appropriate emission filters for fluorescein isothiocyanate 1 and rho-
damine. Digital images were captured using AxioVision software (Zeiss). Negative controls
were established by omitting the primary antibody.
Western blot. Retinal protein extraction or total rMC-1 lysate were incubated with anti-
GFAP (Santa Cruz Biotech), anti-NT (Upstate Biotech), anti-SIRT1 (Santa Cruz), anti-acety-
lated-lys310-RelA/p65-NF-κB (Assay Biotechnology, Sunnyvale, CA), anti-p65 subunit NF-
κBcomplex (Santa Cruz), and anti-NOX4 (Santa Cruz). Immunoreactive bands were visualized
using the enhanced chemiluminescence method (Super Signal CL-HRP Substrate System;
Pierce, Rockford, IL). Exposed films were scanned with a densitometer (Bio-Rad, Hercules,
CA) and analysed quantitatively with Multi-Analyst Macintosh1 Software for Image Analysis
Systems Bio-Rad. As an internal control for protein loadings, the membranes were hybridized
against beta-actin (Santa Cruz). At least three independent experiments were carried out.
SIRT1 activity. SIRT1 activity was measured with a Fluorescent Activity Assay/Drug Dis-
covery Kit designed to measure lysyl-deacetylase (Enzo Life Sciences, Farmingdale, NY).
NAD+-dependent deacetylation of the substrate by recombinant human SIRT1 sensitized it to
Developer II, which then generated a fluorophore. The fluorophore was excited with 360 nm
light, and the emitted light was detected on a fluorometric plate reader (Synergy™Mx;BioTek,
Winooski, VT).
Intracellular ROS levels measured by H2DCF-DA. Intracellular ROS levels were mea-
sured by H2DCF-DA. Relative fluorescence was measured using a fluorescence plate reader
(Synergy™Mx) at excitation and emission wavelengths of 485 and 528 nm, respectively. The
relative fluorescence values were corrected by the number of cells in each treatment.
Covalent modification of SIRT1. Immunoprecipitation was performed as before with
minor modifications [32]. 500 μg of total rMC lysate diluted in extraction buffer were immuno-
precipitated with rabbit anti-SIRT1 (Santa Cruz) using Protein A/G agarose beads. The sam-
ples were subjected to Western blotting against nitrotyrosine (Upstate).
To determine the carbonylation of SIRT1, blots were probed first with anti-SIRT1 antibody
(Santa Cruz). After stripping, the membranes were incubated with 20% methanol, 80% Tris-
buffered saline for 5 min, then incubated with 0.5 mM 2,4-dinitrophenylhydrazine (DNP,
Sigma) to detect carbonyl groups associated with aldehydes and ketones for 30 min at room
temperature. The membranes were washed and then incubated overnight in anti-DNP anti-
body (Merck Millipore, Billerica, MA, USA), as previously described [33].
Statistical analysis
The results were expressed as the mean ± standard deviation. Comparisons between groups
were performed using an analysis of variance followed by Fisher’s protected least-significant
difference test. The analyses were performed using StatView software (SAS Institute Inc., Cary,
NC). P<0.05 was considered significant.
Results
The characteristics of the db/m and db/db mice treated or not with EOC or EOC-CM infusions
and non-diabetic or diabetic WKY rats are presented in Table 1.
To investigate the effects of EOC administration on the diabetic retina, GFAP and VEGF
expressions were assessed as markers of retinal glial reaction and early DR, respectively (Fig 1).
The db/db non-treated mice expressed higher GFAP immunolabeling in the retinal ganglion
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cell layer compared to the db/m mice (P = 0.001) (Fig 1A and 1B). Similarly, there was an
increase in VEGF immunoreactivity compared to the db/m mice (P<0.0001) (Fig 1A and 1C).
Intravenous injection of EOCs prevented these alterations in the diabetic retinas (P<0.02).
Nitrotyrosine(NT) and 8-OHdG expressions were assessed as indices of nitrosative and oxida-
tive stress tissue damage, respectively. There was a marked increase in NT and in 8-OHdG
immunolabeling in retinal tissue from the db/db mice compared to the db/m control animals
(P<0.0001) (Fig 1A and 1D and 1E).EOC intravenous infusion protected the diabetic retinas
from the increment of NT and 8-OHdG expressions (P<0.02 compared with DPBS treated
db/db mice).In order to demonstrate the endocrine mode of action of the cell therapy presented
herein, diabetic mice were randomized to receive intravenous injections of db/m EOC-CM or
unconditioned medium (Fig 2). The retinal protective effects of intravenous infusion of CMwere
similar to those observed in db/db mice treated with EOC infusion. The morphological alter-
ations detected in diabetic retina as GFAP, VEGF and nitrotyrosinewere all prevented in db/db
mice, which received the db/m EOC-CM therapy (P = 0.04, P<0.0001 and P = 0.02, respectively).
This is a demonstration that the EOC therapy displays potent retinal protection under diabetic
conditions and the beneficial effect is attributed to its paracrine capacity. For a better understand-
ing of the underlying mechanism, an in vitro study was conducted.
To address the mechanisms by which EOCs or their CM prevented the diabetic milieu
abnormalities observed in retinal tissue, rMCs were exposed to HG condition in presence or
not of db/m EOC-CM. As observed in the in vivo study, EOC-CM was efficient in preventing
GFAP and VEGF alterations (Fig 3A). Since these structural abnormalities were accompanied
by oxidative stress damage in retinal tissue, we assessed NOX4 expression, a subunit of
NADPH oxidase that is highly correlated with chronic diabetic complications.[34,35] rMCs
under HG display a higher expression of NOX4 compared to NG conditions, which was signifi-
cantly reduced by EOC-CM treatment (P = 0.0003) (Fig 3B). As a consequence, the production
of total reactive oxygen species (ROS) was dramatically reduced in rMCs exposed to diabetic
milieu in presence of EOC-CM (P = 0.002) (Fig 3C). These findings indicate that EOC admin-
istration exerts antioxidant effects in retinal cells exposed to HG through amelioration of the
NADPH oxidase pathway.
Table 1. Physiologic parameters of the studied animals treated or not with EOC or ECO-CM intrave-
nous injections.
Animals Body weight Blood glucose
(g) (mmol/l)
db/m (n = 5) 26.6 ± 1.8 5.76 ± 1.0
db/db + DPBS (n = 4) 45.5 ± 4.9 * 26.2 ± 9.3 †
db/db + EBM2 (n = 8) 48.0 ± 2.8 * 22.4 ± 8.8 †
db/db + EOC (n = 5) 48.0 ± 3.0 * 21.6 ± 9.5 †
db/db + EOC-CM (n = 10) 47.1 ± 4.2 * 21.0 ± 5.7 †
WKY-CT (n = 5) 413,2 ± 66.9 8.7 ± 0.8
WKY-DM (n = 4) 258,8 ± 39.6 ** 31 ± 1.8 ††
WKY-DM+EBM2 (n = 4) 254.4 ± 35.6 ** 30 ± 1.5 ††
WKY-DM+EOC-CM (n = 4) 230,1 ± 19.9 ** 31.4 ± 1.3 ††
*P <0.0001 and
† P <0.0006 vs db/m
** P<0.0002 and
††P<0.0001 vs WKY-CT.
doi:10.1371/journal.pone.0147978.t001
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Fig 1. Intravenous injection of EOCs prevented diabetic retinopathy and oxidative retinal damagemarkers in db/dbmice. (a) Representative
photomicrograph of glial reactivity (GFAP), VEGF, nitrotyrosine (NT) and 8-OHdG in retinal tissue frommice treated with EOC. Magnification X400. (b-e)
Semiquantitative analyses of immunolabeling.The semi quantitative analyses were performed using the Leica Application Suite (Leica Microsystems,
Wetzlar, Germany) in nine non-consecutive retinal sections divided among three slides per animal, per group, under high-powered microscopic viewing
(×400) (Zeiss, Jena, Germany).
doi:10.1371/journal.pone.0147978.g001
Fig 2. Intravenous injection of EOC-CM prevented retinopathy and oxidative damagemarkers in retina from diabetic mice. (a) Representative
photomicrograph of astroglial reactivity (GFAP), VEGF and nitrotyrosine (NT) in retinal tissue frommice treated with EOC-conditioned medium (EOC-CM).
Magnification X400. (b-d) Semiquantitative analyses of immunolabeling. Semiquantitative analyses were performed. The semi quantitative analyses were
performed using the Leica Application Suite (Leica Microsystems, Wetzlar, Germany) in nine non-consecutive retinal sections divided among three slides per
animal, per group, under high-powered microscopic viewing (×400) (Zeiss, Jena, Germany).
doi:10.1371/journal.pone.0147978.g002
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As oxidative stress is the upstream event in sirtuin regulation, we assessed the SIRT-1
expression and activity in rMCs under diabetic conditions. An immunofluorescence assay
revealed that SIRT1, which is a nuclear factor in its active form, is highly expressed in normal
conditions. HG exposure to rMCs induced a marked decrease in the nuclear expression accom-
panied by translocation to cytosol; treatments with EOC-CM re-established SIRT1 nuclear
positivity (Fig 4A). SIRT1 activity evaluated through a fluorometric assay revealed that rMC-1
cells exposed to the HG conditions displayed lower SIRT1 activity (P< 0.0001). The presence
of EOC-CM prevented this abnormality (P = 0.01) (Fig 4B). To demonstrate the role of SIRT-1
activation on EOC-CM treatment effects, the rMCs were treated with siRNA for SIRT-1 (Fig
4B and 4D) orwith specific inhibitor EX-527 (Fig 4C and 4E). Cells exposed to HG conditions
displayed an increase in total acetylated lysine protein with a 2.8-fold increment of Lys310-
RelA/p65 acetylation (P<0.0001). The treatment with EOC-CM caused a decrease in this level
(P = 0.004 and P = 0.002, respectively) indicating a significant improvement in SIRT1 activity.
The presence of the siRNA or SIRT1 inhibitor thoroughly abolished this effect. As expected,
the presence of either siRNA or EX-527 abolished the effects observed in rMC exposed to HG
leading to increment of p65-NFkB subunit acetylation (Fig 4D and 4E, respectively). As
observed in the in vivo study, EOC-CM was efficient in preventing GFAP and VEGF
Fig 3. EOC-CM reduced GFAP and VEGF expressions and prevented glucose-induced ROS production by downregulating NOX4 expression in
rMC-1 under diabetic milieu. (a) Representative photomicrograph of GFAP and VEGF immunofluorescence in rMC-1 cultured for 24 hours in high glucose
(HG) in presence or not of EOC-CM; magnification: X630. (b) Representative Western blots for NOX4 in rMC-1.Equal loading and transfer were ascertained
by reprobing the membranes for ß-actin. (c) The quantification of total intracellular reactive oxygen species (ROS) levels in rMC-1. Values were corrected by
the number of cells at the end of each treatment.
doi:10.1371/journal.pone.0147978.g003
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alterations present in rMCs under diabetic milieu (Fig 5A and 5B). As demonstrated that
NOX4-NADPH subunit is upregulated in rMCs exposed to HG conditions, we aimed to inves-
tigate the cross-talk between SIRT-1 and NOX4-NADPH-oxidase systems. In rMCs under HG
conditions, the silencing of NOX4 gene incited an increment of about 25% SIRT1 activity
(P< 0.0001) (Fig 6A); the combination with CM did not add further effect. This finding indi-
cates that SIRT1 is pivotal in EOC-CMmechanism of action, and that the protective are at
least partly mediated by re-establishment of NOX4-NADPH-oxidase subunit.Finally, in order
to further understand the mechanism by which EOC-CMs modulate SIRT1 activity, we
assessed the possible posttranslational modification of SIRT1 protein in the HG condition.
rMCs exposed to HG displayed a significant increase in SIRT1 carbonylation and nitrosylation
modifications (P<0.0001) (Fig 6B). The treatment with db/m EOC-CMs decreased these mod-
ifications (P<0.0003), thus indicating that EOC-CM prevents carbonylation and nitration
modifications on SIRT1 moleculesin diabetic milieu conditions.
As a proof of concept, the expression of SIRT1 was verified in retinal tissues from db/db
mice. Diabetic mice treated with either EOCs (Fig 7A) or their CM (Fig 7B) via intravenous
infusion displayed a marked improvement inSIRT1 retinal expression. This phenotype is
accompanied by improvement of NOX4 and SIRT1 deacetylation of Lys 310-p65 NFkB sub-
unit (Fig 7A–7F).
To determine whether EOC-CM is capable of preventing visual disturbances in diabetic rats,
retinal function was estimated through full-flash ERG. Diabetic WKY rats showed a significant
decrease in the amplitude of the b-waves and oscillatory potentials accompanied by increase in
implicit time responses. This functional alteration on retinal responses reflects impairment of
inner retinal layers. The intravenous injections of EOC-CM improved those parameters to
Fig 4. EOC-CM improved SIRT1 deacetylation pathway in rMC-1 exposed to high glucose conditions. (a) Immunofluorescence for SIRT1 in rMC-1
cultured for 24 hours. In normal glucose (NG), the SIRT1 signal was stronger and present in the nucleus; in high glucose (HG), the staining becomes faint
and appears to be located predominantly in the cytosol; magnification X1000. (b-c) SIRT1 activity in rMC-1 cultured for 24 hours under different conditions
was estimated by the fluorescent method. (d-e) Representative Western blots for acetyl-Lys310-RelA/p65 in rMCs-1 exposed to HG in presence or not of
EOC-CM combined or not with SIRT1 siRNA (d) or EX-527 (e). Equal loading and transfer were ascertained by reprobing the membranes for ß-actin.
doi:10.1371/journal.pone.0147978.g004
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normal levels (P<0.03), thus restoring the retinal function (Fig 8). This finding reveals that the
endocrine capacity of EOCs may be a possible new therapeutic tool for DR treatment.
Discussion
In this study, cell therapy using EOCs or using the CM either from db/m or from isogenic rat
WKY cultured EOCs were shown to be potential therapies preventing of the early changes in
DR. Both treatments prevented oxidative damage, avoided the glial reaction and VEGF expres-
sion levels increment. In diabetic WKY rats, the retinal function evaluated through eletroreti-
nography was restored in cell-free therapy through intravenous injection of CM. As a lack of
cell retention in injured tissue previously demonstrated [14] the high endocrine capacity of
these cells allows them to act at distant sites. For retinal treatment, this is an advantage, since
no direct manipulation of the eye is needed. The mechanistic pathways involved in these effects
were studied in cultured retinal Müller cells. The rMCs exposed to HG treated with EOC-CM
showed improvement in SIRT1 activity through modulation of the NOX4–NADPH oxidase
subunit, thus reducing ROS formation. This process led to the deacetylation of Lys310-p65,
which downregulated the expression of VEGF and GFAP proteins. The complete proteome
analyses of the conditioned medium from EOCs shown previously by Gilbert and collaborators
[15] described approximately 300 proteins, including GST1, Prdx, Trx, and NADP+, which
contribute to the antioxidant effects observed in EOC-treated mice. The observation that NOX
Fig 5. GFAP and VEGF proteins were downregulated by EOC-CM in rMC-1 under diabetic conditions
through SIRT1 signaling. (a-b) Representative Western blots in total cell lysate against GFAP and VEGF.
Equal loading and transfer were ascertained by reprobing the membranes for ß-actin.rMCs-1 exposed to HG
and treated with EOC-CMs in presence or not of SIRT1 siRNA (a) or EX-527, a SIRT1 inhibitor, (b). The
efficiency of the SIRT1 siRNA(100nM) was ~59%.
doi:10.1371/journal.pone.0147978.g005
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expression/activity can be modulated by antioxidant enzyme defences is supported by previous
work in renal cells, where the NOX subunit is simultaneously the target and agonist of TGF-β
[36]. Indeed, most agents that improve renal pathology prevent the increase of NOX compo-
nents [37]. The high antioxidant capacity of these cells, equilibrating the redox status, pre-
vented the posttranslational modifications on the SIRT1 molecule from restoring its activity
under diabetic conditions.
Since the landmark paper by Asahara [38], EPCs have been the center of regenerative medi-
cine, mainly involving cardiovascular diseases and neovascularisation [39,40]. Herein, the
treatment with systemic EOCs or their CM invoked protection of retinal tissue from diabetes
insult due to its high antioxidant property, thus leading to reestablishment of SIRT1 activity. In
conclusion, compelling evidence is provided that equally beneficial effects were observed in
treatments using EOCs or their CM, promoting retinal protection from glucose-related oxida-
tive damage. Further studies using conditioned media from EOCs are needed in order to pro-
vide evidences of possible efficiency for autologous EOC therapy in patients with diabetic
retinopathy.
Fig 6. EOC-CM prevents SIRT1 post-translational modification and improved SIRT1 activity throughNOX4–NADPH oxidasedownregulation in
rMC-1. (a) SIRT1 activity in rMC-1 cultured for 24 hours by a fluorescent method. Cells in NG or HG conditions were exposed to NOX4siRNA in presence or
not of db/m EOC-CM or db/db EOC-CM. Representative Western blots for NOX4 in rMC-1 total lysate cultured for 24 hours in HG. The efficiency of the
NOX4small interfering RNA (100nM) was ~63%.NS = no significant difference. (b) SIRT1 immunoprecipitation in rMCs-1 lysates exposed to HG in presence
of EOC-CM. Carbonylation was detected by first derivitizing the samples with DNPH and immunoblotting with DNP antibody. Nitration was detected by
immunoblottingwith nitrotyrosine (NT) antibody.
doi:10.1371/journal.pone.0147978.g006
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Fig 7. EOC or EOC-CM intravenous injections treatments improve retinal Sirt1 pathway in db/dbmice. (a) A representative photomicrograph of
immunolocalization of Sirt-1 in retinal tissue frommice treated with EOC. (b) Western blot for NOX4, Sirt1 and acetyl-Lys310-p65 subunit-NFkBexpression in
mice retinal tissue lysate. Equal loading and transfer were ascertained by reprobing the membranes for ß-actin. (b-e) The arbitrary unit of densitometry was
transformed to folders of increment in relation to the media of db/m in each experiment to compare independent experiments. (f) A representative
photomicrograph of immunolocalization of Sirt1 in retinal tissue frommice treated with EOC-conditioned medium (EOC-CM).
doi:10.1371/journal.pone.0147978.g007
Fig 8. EOC-CM intravenous injection treatment restores retinal function in diabetic WKY rats.Representative waveforms of b-waves and oscillatory
potentials in the studied rats. The b-wave is the positive deflection generated in part by the Müller and mainly by the bipolar cell potentials. The figure shows
representative full-flash ERG waveforms and oscillatory potentials at 0.25 cd.s/m2 for a non-diabetic (WKY-CT, red), diabetic untreated (WKY-DM, green),
diabetic treated with EBM2medium (WKY-DM+EMB2, purple) and diabetic treated with EOC-conditioned medium (WKY-DM+EOC-CM, blue). The bars
represent mean±S.D. of b-wave ampliutude (μv), implicit time (ms) and oscillatory potentials (μv) from all animal groups.
doi:10.1371/journal.pone.0147978.g008
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